- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00902291
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
A disease assessment will be performed at study week 8 (± 3 days) by the investigator. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may continue to receive treatment based on their original treatment assignment until disease progression or intolerability. Disease assessments will be performed every 8 weeks during the extended period. A safety follow-up visit will occur 4 weeks after the last dose infusion of AGS-1C4D4 and/or gemcitabine.
Post-Treatment: Subjects terminating from protocol therapy for reasons unrelated to documented disease progression will be followed by telephone contact every 2 months until they begin a new anticancer therapy, their disease progresses, they die, become lost to follow-up or withdrawal consent for further follow-up, whichever of these events occurs first.
Overall survival: All subjects will be followed by telephone contact every 2 months until death, loss to follow-up, or withdrawal of consent, whichever of these events occurs first.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
-
-
-
Arkhangelsk, Den russiske føderasjonen
- State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
-
Ivanovo, Den russiske føderasjonen
- Regional Oncology Dispensary
-
Kazan, Den russiske føderasjonen
- Clinical Oncology Dispensary of Republic of Tatarstan
-
Kuzmolovo, Den russiske føderasjonen
- State Healthcare Institution "Leningrad Regional Oncologic Dispensary"
-
Moscow, Den russiske føderasjonen
- Non-state Healthcare Institution N.A. Semashko Central Clinical Hospital #2 of JSC "Russian Railway"
-
Obninsk, Den russiske føderasjonen
- Medical Radiology Research Center of Russian Medical Academy
-
Omsk, Den russiske føderasjonen
- State Healthcare Institution of Omsk Region "Clinical Oncologic Dispensary"
-
Saint Petersburg, Den russiske føderasjonen
- State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
-
St. Petersburg, Den russiske føderasjonen
- Saint Petersburg State Healthcare Institution "Municipal Clinical Oncology Dispensary"
-
-
-
-
California
-
La Jolla, California, Forente stater, 92093
- University of California San Diego Medical Center
-
-
Florida
-
Boynton Beach, Florida, Forente stater, 33435
- Palm Beach Institute of Hematology and Oncology
-
Miami, Florida, Forente stater, 33136
- University of Miami
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70809
- Medical Oncology LLC
-
-
Maryland
-
Annapolis, Maryland, Forente stater, 21401
- Annapolis Oncology Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Dana Farber Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55407
- Virginia G. Piper Cancer Center
-
-
New York
-
New York, New York, Forente stater, 10021
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, Forente stater, 13210
- Regional Oncology Center
-
-
Oregon
-
Portland, Oregon, Forente stater, 97227
- Kaiser Permanente Northwest Region Oncology Hematology
-
-
South Carolina
-
Greenville, South Carolina, Forente stater, 29605
- Cancer Centers of the Carolinas
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37920
- Baptist Regional Cancer Center
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt University Medical Center, Div. of Medical Oncology
-
-
Virginia
-
Lynchburg, Virginia, Forente stater, 24501
- Alan B. Pearson Regional Cancer Center Lynchburg Hematology Oncology Clinic
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Medical College of Wisconsin
-
-
-
-
-
Clermont-Ferrand, Frankrike
- CHU Estaing
-
Le Mans Cedex, Frankrike
- Centre Jean Bernard, Oncologie médicale
-
Lille, Frankrike
- Centre Régional de Lutte Contre le Cancer-Centre Oscar Lambret
-
Pessac, Frankrike
- Hôpital du Haut Lèvêque, Service d'Hepato Gastroentérologie
-
Poitiers Cedex, Frankrike
- Centre Hospitalier Universitaire de Poitiers
-
Rouen, Frankrike
- Hôpital Charles Nicolle
-
-
-
-
-
Barcelona, Spania
- Hospital Clinic i Provincial de Barcelona, Servicio de Oncologia
-
Madrid, Spania
-
Toledo, Spania
- Hospital Virgen de la Salud, Servicio Oncologia
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Pathologically confirmed metastatic adenocarcinoma of the pancreas (AJCC Stage IV). Subjects with islet cell neoplasms are excluded
- Non-measurable or measurable disease based on the RECIST criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Life expectancy of > 3 months
Hematologic function, as follows:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL (transfusion independent)
Renal function, as follows:
- Creatinine ≤ 2.0 mg/dL
Hepatic function, as follows:
- Aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases.
- Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases
- Bilirubin ≤ 2 x ULN
- INR < 1.3 (or ≤ 3 if on warfarin for therapeutic anti-coagulation)
Exclusion Criteria:
Prior systemic therapy for metastatic pancreatic cancer
- Subjects who have received adjuvant treatment with gemcitabine and who had relapse metastatically are allowed
- Subjects with advanced local disease who have received treatment with gemcitabine and in whom progression has been observed with the onset of metastases less than 6 months are excluded
- Chemotherapy and/or radiation within 4 weeks of study enrollment
- Prior monoclonal antibody therapy within 60 days of study enrollment
- Known brain or leptomeningeal disease
History of other primary malignancy, unless:
- Curatively resected non-melanomatous skin cancer
- Other malignancy curatively treated with no known active disease present and no treatment administered for the last 3 years
- Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System)
- Use of any investigational product within 4 weeks of study enrollment
- Major surgery (that requires general anesthesia) within 4 weeks before study enrollment
- Women who are pregnant (confirmed by positive pregnancy test) or lactating
- Man or woman of childbearing potential not consenting to use adequate contraceptive precautions during the course of the study and for 4 weeks after the last AGS-1C4D4 and/or gemcitabine infusion administration
- Subject known to be human immunodeficiency, hepatitis B or hepatitis C virus positive
- Active serious infection not controlled with antibiotics
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: 1. Gemcitabine monotherapy
|
IV infusion
|
Eksperimentell: 2. Gemcitabine plus AGS-1C4D4
|
IV infusion
IV infusion
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Survival rate at 6 months
Tidsramme: 6 months
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Overall Survival (OS)
Tidsramme: Throughout treatment period and post-treatment every 2 months until death, or subject discontinues the study
|
Throughout treatment period and post-treatment every 2 months until death, or subject discontinues the study
|
Progression free survival (PFS)
Tidsramme: Throughout treatment period or post-treatment every 2 months until disease progression or death, respectively, or subject discontinues the study
|
Throughout treatment period or post-treatment every 2 months until disease progression or death, respectively, or subject discontinues the study
|
Change in level of serum tumor marker CA 19-9
Tidsramme: Week 1, Week 4, Week 7 and every 3 weeks during the extended treatment period
|
Week 1, Week 4, Week 7 and every 3 weeks during the extended treatment period
|
Incidence of anti-AGS-1C4D4 antibody formation
Tidsramme: Week 1, Week 7 and every 8 weeks during the extended treatment period
|
Week 1, Week 7 and every 8 weeks during the extended treatment period
|
Objective Response Rate (Partial Response or better per RECIST criteria version 1.1
Tidsramme: Week 8, and every 8 weeks during the extended treatment period
|
Week 8, and every 8 weeks during the extended treatment period
|
Disease Control (Stable Disease or better per RECIST criteria)
Tidsramme: Week 8, and every 8 weeks during the extended treatment period
|
Week 8, and every 8 weeks during the extended treatment period
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Chief Medical Officer, Agensys, Inc.
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer etter nettsted
- Adenokarsinom
- Karsinom
- Neoplasmer, kjertel og epitel
- Sykdommer i det endokrine systemet
- Neoplasmer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Neoplasmer, duktale, lobulære og medullære
- Karsinom, Ductal
- Neoplasmer i bukspyttkjertelen
- Pankreassykdommer
- Karsinom, bukspyttkjertelduktal
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Enzymhemmere
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Gemcitabin
Andre studie-ID-numre
- 2008002
- 2009-009194-99 (EudraCT-nummer)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Bukspyttkjertelkreft
-
Tianjin Medical University Cancer Institute and...Har ikke rekruttert ennåPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Cedars-Sinai Medical CenterRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaForente stater
-
Radboud University Medical CenterDutch Cancer SocietyRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaNederland
-
Thomas Jefferson UniversityUkjentBukspyttkjertelfistel | Distal pankreatektomikomplikasjoner | Falciform Patch Pancreatic Closure | Fibrinlim bukspyttkjertellukkingForente stater
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... og andre samarbeidspartnereRekrutteringBukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannia
-
Chinese PLA General HospitalRekrutteringNeoplasmer i bukspyttkjertelen | Bukspyttkjertelkreft | Bukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaKina
-
Andrei IagaruIkke lenger tilgjengeligKarsinoide svulster | Islet Cell (Pancreatic NET) | Andre nevroendokrine svulsterForente stater
Kliniske studier på Gemcitabine
-
AstraZenecaRekrutteringGaldeveiskreftFrankrike, Spania, Italia, Korea, Republikken, Japan, Tyskland, Forente stater, Singapore
-
Sierra Oncology LLC - a GSK companyFullførtAvanserte solide svulsterSpania, Storbritannia
-
University of Erlangen-Nürnberg Medical SchoolFullførtBukspyttkjertelkreftTyskland
-
Shenzhen University General HospitalHar ikke rekruttert ennå
-
Kansai Hepatobiliary Oncology GroupFullført
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRekruttering
-
3D Medicines (Sichuan) Co., Ltd.Har ikke rekruttert ennåNeoplasmer i galleveiene
-
Samsung Medical CenterFullførtBukspyttkjertelkreftKorea, Republikken
-
University of ZurichAvsluttetBukspyttkjertelkreftFrankrike, Sveits, Belgia, Tyskland
-
HutchmedFullførtLymfom | Osteosarkom | Solid svulst | Ewing Sarkom | Rhabdomyosarkom | Ikke-rabdomyosarkom bløtvevssarkomForente stater